Introduction: The impact of sleep on quality of life (QoL) has been well documented; however, there is a great need for reliable QoL measures for persons with obstructive sleep apnea (OSA). We compared the QoL scores between the 36-Item Short Form of the Medical Outcomes Survey (SF-36), Calgary Sleep Apnea Quality of Life Index (SAQLI), and Functional Outcomes Sleep Questionnaire (FOSQ) in persons with OSA. Methods: A total of 884 participants from the Sleep Heart Health Study second examination, who completed the SF-36, FOSQ, and SAQLI, and in-home polysomnograms, were included. The apnea hypopnea index (AHI) at 4% desaturation was categorized as no OSA (<5 /hour), mild to moderate OSA (5-30 /hour) and severe OSA (>30 /hour). QoL scores for each questionnaire were determined and compared by OSA severity category and by gender. Results: Participants were 47.6% male, 49.2% (n=435) had no OSA, 43.2% (n=382) had mild to moderate OSA, and 7.6% (n=67) had severe OSA. Participants with severe OSA were significantly older (mean age = 63.7 years, p <.0001), had higher BMI (mean = 34.3 kg/m 2 , p <.0001) and had lower SF-36 Physical
Introduction:
Obstructive sleep apnea (OSA) is a highly prevalent condition occurring in as many as 17% and 9% of middle aged males and females, respectively.(1) OSA is now recognized as an important risk factor for the development of hypertension and coronary heart disease as well as premature death. (2) However, patients frequently present to health care providers with symptoms that are indicative of impairment in their quality of life (QoL). Improvement in QoL is an important determinant of whether patients adhere to continuous positive airway pressure (CPAP), the most commonly prescribed treatment for OSA. Additionally, measurement of QoL is one of the quality metrics recently developed for use in clinical practice,(3) thus increasing the importance of evaluating tools used to assess QoL in OSA.
A variety of tools to measure QoL have been utilized in epidemiologic studies and clinical trials of OSA. The most common general QoL instrument used has been the Medical Outcomes Study Short-Form Health Survey SF-36.(4) More recently, two sleep specific QoL questionnaires have been developed, the Functional Outcomes of Sleep Questionnaire (FOSQ) (5) and the Sleep Apnea Quality of Life Inventory (SAQLI). (6) Whether these sleep specific QoL instruments are more sensitive in those with OSA than general QoL questionnaires is not clear. Furthermore, there have been few comparisons of the FOSQ to the SAQLI with respect to their sensitivity in those with OSA and whether QoL differs between males and females. Using data from a large cohort study, the purposes of these analyses were to compare these instruments to each other, to assess whether they were able to detect differences in QoL among groups with different severities of OSA and to determine whether there were differences between genders.
Methods:
The Sleep Heart Health Study (SHHS) is a prospective multicenter cohort study designed to investigate the relationship between OSA and cardiovascular diseases in the United States. Details of the study design have been published elsewhere. (7) Briefly, initial baseline recruitment began in 1995, enrolling 6,441 subjects, 40 years of age and older, from several ongoing geographically distinct cardiovascular and respiratory disease cohorts who were initially assembled between 1976 and 1995. ( The SHHS was approved by the respective institutional review boards for human subjects research, and informed written consent was obtained from all subjects at the time of their enrollment into each stage of the study.
Polysomnography
Participants underwent overnight in-home polysomnograms using the Compumedics Portable PS-2 System (Abbottsville, Victoria, Australia) administered by trained technicians.(9) Briefly, after a home visit was scheduled, the Sleep Health Questionnaire, SF-36, SAQLI, and FOSQ questionnaires generally were mailed 1 to 2 weeks prior to the in-home polysomnography appointment. Each participant was asked to complete the questionnaire before the home visit, at which time the questionnaires were collected and verified for completeness. The home visits were performed by twoperson, mixed-sex teams in visits that lasted 1.5 to 2 hours. There was emphasis on making the night of the polysomnographic assessment as representative as possible of a usual night of sleep. Participants were asked to schedule the visit so that it would occur approximately two hours prior to their usual bedtime. Participants' weekday or weekend bedtime routines were encouraged to be consistent with the day of the week that the visits were made. 
Sleepiness
The level of daytime sleepiness was determined using the Epworth Sleepiness Scale (ESS), a validated 8-item questionnaire that measures subjective sleepiness. (14) Subjects were asked to rate how likely they are to fall asleep in different situations. Each question was answered on a scale of 0 to 3.
ESS values ranged from 0 (unlikely to fall asleep in any situation) to 24 (high chance of falling asleep in all 8 situations). Mean ESS scores between 14 and 16 have been reported for patients with OSA. (14, 15) Scores of 11 or greater are considered to represent an abnormal degree of daytime sleepiness. (16) Sleepiness was defined as an ESS of at least 10. 
Quality of Life Measures

Functional Outcomes Sleep Questionnaire (FOSQ)
The FOSQ was developed as a self-report instrument to assess the disorders of sleepiness on quality of life. It consists of 30 items with 5 factor-based subscales: activity level, vigilance, intimacy and sexual relationships, general productivity and social outcome. A mean weighted item score is obtained for each subscale. The subscales are summed to produce a global score. (5) In SHHS, questions related to sexual intimacy were omitted because there were concerns that some participants would find these embarrassing or offensive.
Sleep Apnea Quality of Life Index (SAQLI)
The SAQLI was developed as a sleep apnea specific quality of life instrument. Separate multivariate linear regression models were fitted to evaluate scores from each of the four QoL scales by OSA categories for males and females. Potential confounders (age, race, COPD, chronic bronchitis, ESS and asthma) were evaluated and adjusted for in the models; only those variables with significant coefficients were kept in the models. Thus, OSA severity, ESS, and asthma were the only variables retained in the final models. All statistical tests were performed using statistical software (Stata SE, version 13.0 for Windows; Stata Corp; College Station, TX) and a significance level of 0.05.
Results:
Participants were 47.6% male and 52.4% female, 49.2% (n=435) had no OSA, 43.2% (n=382) had mild to moderate OSA, and 7.6% (n=67) had severe OSA. Approximately 21% of participants with mild to moderate OSA and 39% of those with severe OSA reported excessive daytime sleepiness (ESS >10) (Table 1) . Participants with severe OSA were significantly older (mean age = 63.7 years, p <.0001), had higher BMI (mean = 34.3 kg/m 2 , p <.0001) and had lower SF-36 PCS scores (45.1, p= .006) than participants with no OSA or those with mild to moderate OSA. There was also a trend towards lower scores on the MCS of the SF-36, the SAQLI, and the FOSQ ( Table 2) .
When analyzed according to gender, no significant differences were found in males for QoL by OSA severity categories (Table 3) . Males with severe OSA had significantly higher BMI (mean 31.9, p<.0001) than males with no OSA or males with mild to moderate OSA. However, as shown in Table 4 , females with severe OSA had significantly lower mean scores for the SAQLI (5.4, p= .006), FOSQ (10.9, p= .02), and SF-36 PCS (37.7, p<.0001) compared to females with no OSA and those with mild to moderate OSA. Females with severe OSA also had significantly higher BMI (mean 41.8, p<.0001) than females with no OSA or females with mild to moderate OSA. Table 5 , comparisons between the QoL measures showed small correlations between the FOSQ and the SF-36 MCS (r=.31, p < .001) and the SF-36 PCS (r=.37, p <.001), and medium correlations between the SAQLI and the SF-36 MCS (r=0.52, p <.001) and the SF-36 PCS (r=.42, p < .001).
As shown in
The correlation between the SAQLI and FOSQ was 0.66, p <.001, and the correlation between SF-36 MCS and SF-36 PCS was -.024, however this was not significant (p = .142). In addition, ESS scores were inversely correlated with the SAQLI (r = -.36), FOSQ (r = -.43), MCS (r = -.17), and PCS (r = -.16) (data not shown).
Because categorical analyses showed no difference for males in QoL scores, we, therefore, ran linear regression models separately for females and males ( Table 6 ). In these analyses, AHI severity was significant only for the SF-36 PCS in females with severe OSA. (coeff. = -8.3, p=.004). In contrast, the ESS was significant in models for all of the instruments in both males and females. The only other factor entering into some models was asthma, which was significant in models of the SAQLI and the PCS in females.
Discussion:
In these analyses using a general (SF-36) and two sleep specific QoL assessment tools (FOSQ and SAQLI), we found that QoL was reduced in those with severe OSA; substantial differences were not apparent among participants with mild to moderate OSA and those with no OSA. However, there were significant gender disparities. Females with severe OSA demonstrated a substantial reduction in QoL with all instruments, but there was a lack of differences among males by OSA severity. The reductions in QoL were explained primarily by the presence of sleepiness. Furthermore, correlations among QoL questionnaires were modest at best, indicating that they assess different QoL domains.
When males and females were analyzed together in our study, only the PCS of the SF-36 showed a significant reduction in QoL in participants with OSA, but this was limited solely to participants with severe OSA. Additional studies also have found lower QoL only in those with severe OSA. (19, 20) Moreover, other studies have failed to find any differences in QoL among participants with a broad spectrum of OSA severity. (21) (22) (23) In one of these studies, Lee and colleagues (22) found that the AHI was not associated with differences in the PCS or MCS of the SF-36 in a large group of patients seen in a sleep clinic. In their study, other factors, such as age, gender, minimum oxygen saturation, sleepiness, and depression were associated with the PCS or MCS scores. Our study also found a strong trend between sleepiness and QoL scores for females and males. Similarly, in a smaller study, Le et al (22) did not find differences in the SAQLI among OSA patients of different severities. Our data also are consistent with a previous analysis from the first examination of SHHS in which severe OSA was associated with worse QoL on most subscales of the SF-36, but only the vitality subscale was reflective of poorer QoL in participants with OSA of less severity. In contrast, even mild OSA was associated with reduced QoL in comparison to no OSA among the middle-aged males and females of the Wisconsin Sleep Cohort. (24) However, our cohort was older than participants in the Wisconsin Sleep Cohort and only a small sample from the SHHS was analyzed in the present study. Thus, age and other demographic differences among the cohorts may provide explanations for these discrepancies. Nevertheless, despite the absence of large cross-sectional differences in QoL as a function of OSA severity, in most studies, the SF-36, SAQLI, and FOSQ have been shown to be sensitive to changes in QoL after OSA treatment.
When analysis of our data was performed separately according to gender, we observed that the reduction in QoL with severe OSA was limited to females irrespective of the QoL instrument. Other studies (22) also have noted that QoL in participants with OSA is worse in women. However, in a study of a large cohort of males, Appleton et al., (25) found that increasing AHI was associated with lower QoL on the SF-36, but only in those less than 69 years of age. The median age of the SHHS cohort is 60 years with substantial numbers of participants older than 70 years. Thus, our results and those of Appleton et al. may not be discrepant necessarily.
Excessive daytime sleepiness is one of the most common symptoms in OSA, and sleepiness can have a profound negative impact on QoL. Thus, not surprisingly, our multivariate analyses demonstrated that the negative impact of severe OSA was explained primarily by the presence of sleepiness. Our finding is consistent with the findings of some, (19, 22, 23, 26) but not all previous studies. (27) The explanation for these inconsistent findings is not readily apparent, but possibilities include whether study populations were recruited from the general population or clinic, as well as whether the cohorts had other co-morbidities that would impact QoL. A differential perception of sleepiness between males and females offers a possible explanation of the greater impact of OSA on QoL in the latter. However, this assertion seems unlikely inasmuch as previous studies indicate females with OSA are more likely to report fatigue rather than sleepiness. (28) (29) (30) We observed that correlations among the SF-36, SAQLI, and FOSQ were relatively weak to moderate. Our results are consistent with the few studies that have done similar comparisons. In a Spanish multicenter study, (21) correlations of the FOSQ and several scales of the SF-36 with the 4 domains of the SAQLI were poor to moderate. They ranged from r=.179 between the FOSQ and SAQLI Emotional Functioning domain to r=.579 for the SF-36 Vitality and SAQLI Daily Functioning domain. In a Polish study, (31) the correlation between the SF-36 and the FOSQ was r=.46 and between the SF-36 and the SAQLI was r=.47. Other studies have compared the SF-36 to other general QoL instruments in patients with OSA, with some, but not all, demonstrating reasonable correspondence. (32, 33) Considering our results with other studies, various instruments may sample different aspects of QoL.
Care should be exercised when selecting a tool to assess health outcomes in OSA.
There are several important limitations to our findings. First, the SHHS cohort was recruited from participants enrolled in other longitudinal studies, many of whom were long-time participants.
These individuals may represent a group of survivors who would generally have better QoL regardless of OSA-severity status. Second, as a group, the SHHS cohort is older (mean age = 61.6 years) and may not be representative of the US adult population. Third, SHHS is a general population cohort, and thus, unlike a clinical cohort, some did not have symptoms of OSA. Finally, severity of OSA may not be best reflected by the AHI. Other markers of severity such as amount of oxygen desaturation or degree of sleep fragmentation may be better surrogates to show differences in QoL. Nevertheless, despite these limitations, our analyses have some unique qualities such as a well-characterized, racially and ethnically diverse cohort, use of home-based polysomnography to assess the severity of OSA, and data related to QoL derived from 3 different instruments.
In conclusion, in a middle-aged to elderly cohort, QoL is poorer only in females with severe OSA.
To a large extent, these findings can be explained by the presence of daytime sleepiness. Correlations among 3 commonly used QoL instruments used in persons with OSA were weak to moderate, suggesting that each samples different aspects of QoL. Therefore, care should be exercised in selecting a QoL tool for documenting health care outcomes for research or clinical care.
Acknowledgments:
The Dr. Silva was supported by NHLBI grant HL 062373-05A2. .99 SF-36 PCS 48.0 (11.0) 44.6 (11.6) 37.7 (11.1) <.0001 *p-value for ANOVA test. 
